پیوندهای مفید
آمار
| تعداد نشریات | 20 |
| تعداد شمارهها | 1,149 |
| تعداد مقالات | 10,518 |
| تعداد مشاهده مقاله | 45,422,778 |
| تعداد دریافت فایل اصل مقاله | 11,296,507 |
Expression of Chemokine Receptors on Th1/Th2 CD4+ Lymphocytes in Patients with Multiple Sclerosis | ||
| Iranian Journal of Immunology | ||
| مقاله 1، دوره 8، شماره 1، خرداد 2011، صفحه 1-10 اصل مقاله (287.39 K) | ||
| نوع مقاله: Original Article | ||
| نویسندگان | ||
| Alireza Andalib* 1؛ Hassan Doulabi1؛ Mohammadreza Najafi2؛ Mehdi Tazhibi3 | ||
| 1Immunology Department | ||
| 2Neurology Department, Isfahan Medical School | ||
| 3Biostatic Department, Isfahan University of MedicalSciences, Isfahan, Iran | ||
| چکیده | ||
| Background: Th1 cells preferentially express CXCR3, CCR5 and CCR6, while CCR3 and CCR4 are predominantly expressed by Th2 cell subsets. Multiple Sclerosis (MS) is a Th1 cell-dependant chronic inflammatory disease of the central nervous system, and immunomudolatory cytokines could alter the chemokine expression pattern of these lymphocyte subsets. Objective: This study was performed to measure chemokine receptor expression on CD4 T cells for evaluation of Th1/Th2 dominantly in IFN-β treated patients. Methods: flowcytometry was used to detect chemokine receptor expression on CD4 T cell population in PBMCs obtained from MS and healthy control groups. Twenty six MS patients participated in this study before and after IFN-β therapy and the same number of healthy individuals were included. Results: The percentage of lymphocytes was 41.28% ± 10.30 in the blood of MS group compared with 36.88% ± 5.51% in the control group (p=0.017). The CD4+CXCR3+ cells were 18.86% ± 8.46% in healthy group, 30.78% ± 9.8% in pre-treated MS patients and 21.06% ± 9.23% in posttreated group (p<0.001). The CD4+CCR4+ cell subsets were 27.35% ± 10.15% in healthy group; 28.17% ± 8.9% in pre-treated group and 34.20% ± 8.96% in the post- IFN-β treatment group. The subset of CD4+CCR4+ was found to be dominant after IFN- β therapy in comparison with the control group (p<0.001). CD4+CCR5+ percentage was 1.24% ± 0.92% in the healthy people, 1.23% ± 0.71% in the MS patients and 0.76% ± 0.49% in post-treatment status (p=0.003). CD4+CCR3+ cell subsets were 0.62% ± 0.67% in control group, 0.28% ± 0.26% in the MS patients (p=0.022) and 0.39% ± 0.54% in IFN-β treated patients (p=0.334). An association was found for CXCR3 expression in pre- and post- treatment status (r=0.840, p<0.001) as well as for CCR4+ expression (r=0.712, p<0.001) in the same groups. The Th1 response was dominant in pre-treatment states, and then it shifted to a Th2 dominant state after IFN-β treatment. Conclusion: We suggest that the chemokine receptor expression of Th1/Th2 cell subsets could be used for monitoring and the evaluation of the MS disease status. | ||
| کلیدواژهها | ||
| Chemokine؛ Receptor؛ Multiple Sclerosis؛ IFN-β؛ Th1؛ Th2 | ||
|
آمار تعداد مشاهده مقاله: 1,310 تعداد دریافت فایل اصل مقاله: 859 |
||